21 YEARS AFTER INTRODUCING SENTINEL LYMPH NODE BIOPSY IN CLINICAL PRAXIS AT THE ONCOLOGY INSTITUTE OF VOJVODINA

Vladimir Selakovic, Milan Ranisavljevic, Dejan Lukic, Mladen Djuric

Abstract


Introduction: Sentinel lymph node biopsy (SLNB) is a standard procedure at the OncologyInstitute of Vojvodina since 1999 and during this period we have done more than 1700 biopsies. The aim of this study was to present our results in SLNB in breast cancer surgery.

Materials and methods: This retrospective study was performed at the Department for Surgical Oncology at the Vojvodina Institute of Oncology in the period from January 1999 to December 2019. The study included 1762 patients who had undergone SLNB. The mean duration of the follow-up period was 121.89 months. All patients were women with clinically T1-2N0-1M0 breast cancer. Preoperatively, all patients were administered dual contrast media, radiotracer, and blue dye.

Results: The majority of tumors were T1c (955 (54.18%). The mean number of extirpated sentinel lymph nodes (SLN) in both groups was 1.84. In 199 (36.72%) patients SLN was the only metastatic lymph node in the axilla.  Micro metastases were found in 113 (21.03%) patients. The overall diagnostic accuracy of SLNB was 96%.

Conclusion: Axillary SLN can serve as a reliable predictor of negativity of other ipsilateral axillary nodes. Micro metastases in the SLN are not an indication for complete axillary lymph node dissection.


Keywords


breast cancer, sentinel lymph node, complete axillary lymph node disection

Full Text:

PDF

References


Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907; 46(1):1–19. doi:10.1097/00000658-190707000-00001

Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomised clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989; 320(13):822-8. doi: 10.1056/nejm198903303201302. Erratum in: N Engl J Med 1994;330(20):1467.

https://doi.org/10.1056/nejm198903303201302

Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997; 15(6):2345–50. doi:10.1200/jco.1997.15.6.2345.

https://doi.org/10.1200/jco.1997.15.6.2345

Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol. 2009; 16(3):687–96. doi:10.1245/s10434-008-0195-5.

https://doi.org/10.1245/s10434-008-0195-5

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs. No axillary dissection on 10-Year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017; 318(10):918-26. doi:10.1001/jama.2017.11470.

https://doi.org/10.1001/jama.2017.11470

Veronesi P, Corso G. Standard and controversies in sentinel node in breast cancer patients. Breast. 2019; 48 (suppl 1):53-6. doi:10.1016/s0960-9776(19)31124-5.

https://doi.org/10.1016/s0960-9776(19)31124-5

Zeitoun J, Babin G, Lebrun JF. Sentinel node and breast cancer: A state-of-the-art in 2019. Gynecol Obstet Fertil Senol. 2019; 47(6):522-6. French. doi:10.1016/j.gofs.2019.04.002.

Pan H, Gray RG, Davies C, Peto R, Bergh JCS, Pritchard KI, et al. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). J Clin Oncol. 2016; 34(15):505. doi:10.1200/jco.2016.34.15_suppl.505.

https://doi.org/10.1200/jco.2016.34.15_suppl.505

Moreno AC, Lin YH, Bedrosian I, Shen Y, Stauder MC, Smith BD, et al. Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. Adv Radiat OncoI. 2017; 2(3):291–300. doi:10.1016/j.adro.2017.04.008.

https://doi.org/10.1016/j.adro.2017.04.008

Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015; 373(4):307–16. doi:10.1056/nejmoa1415340.

El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, et al. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016; 212(5):969–81.doi:10.1016/j.amjsurg.2016.07.018.

https://doi.org/10.1016/j.amjsurg.2016.07.018

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013; 14(7):609–18. doi:10.1016/s1470-2045(13)70166-9.

https://doi.org/10.1016/s1470-2045(13)70166-9

Ranisavljević M, Selaković V, Lukić D, Radovanović Z, Vicko F. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Arch Oncol. 2013; 21(3-4):105-8. doi:10.2298/aoo1304105r.

https://doi.org/10.2298/aoo1304105r

Golubovic A, Ranisavljevic M, Radovanovic Z, Selakovic V, Mandic A, Djilas D. Analysis of sentinel nodes biopsy in breast cancer: 12 years after introduction into clinical practice. Med Pregl. 2012; 65 (9-10): 363-7. doi:10.2298/mpns1210363g.

https://doi.org/10.2298/mpns1210363g

Koolen BB, Donker M, Straver ME, van der Noordaa MEM, Rutgers EJT, Valdes Olmos RA et al. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy. Br J Surg. 2017;104(9):1188–96.doi:10.1002/bjs.10555.

https://doi.org/10.1002/bjs.10555




DOI: http://dx.doi.org/10.24125/sanamed.v16i1.471

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Vladimir Selaković, Milan Ranisavljević, Dejan Lukić, Mladen Đurić

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.